C
Center for Breakthrough Medicines
Complete Solution for the Discovery, Development, and Commercialization of Cell and Gene Therapies
About Center for Breakthrough Medicines
The Center for Breakthrough Medicines (CBM) is a leading player in the pharmaceutical and biotechnology industry. Its primary mission is to expedite the development and manufacturing of advanced therapies, with an aim to save lives. CBM serves a broad range of clients, including pharmaceutical and biotechnology companies, by assisting them throughout the entire process of advanced therapy development. This includes research and development, manufacturing, and commercialization.
CBM operates in the global market, leveraging its wide range of services, global capabilities, and a team of skilled experts to ensure accelerated and precise progress towards the market. The company has over 20 viral vector suites and cell processing suites, 200 L GMP plasmid manufacturing, and more than 180 analytical assays. These facilities are designed to shorten the turnaround on manufacturing Adeno-Associated Viruses (AAVs), providing more flexibility to developers in producing viral vectors for clinical and commercial use.
The company's business model is based on strategic partnerships and collaborations. For instance, CBM has partnered with SK Pharmteco, Cell One Partners, Nucleus Biologics, and Stoic Bio to expand its capabilities and accelerate the commercialization of cell and gene therapies. It also offers pre-clinical packages with plasmids, cell line, and pre-clinical vector manufacturing.
In terms of revenue, CBM makes money by providing services to its clients. These services range from research and development support to manufacturing and commercialization of advanced therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 67
- Open positions
- None listed
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Genetics and genomics, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2022 | $350M | $1.4B | SK Inc · SK Group | ↗ |
Growth signals
Latest recorded traffic for Center for Breakthrough Medicines is 160 monthly website visits, down 75% over the last three months. Center for Breakthrough Medicines's team declined 15.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Center for Breakthrough Medicines in the Upper Merion Township ecosystem
The Center for Breakthrough Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
SK Group
SK Inc
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Center for Breakthrough Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Center for Breakthrough Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








